All Posts

Dr. Newbold brings over 30 years of business development and alliance management experience to EDI, having led business teams in negotiating over $1.5 billion in announced pharma and biotech deals.

The journey from academic idea to therapeutic application has many inherent challenges that can keep potential breakthrough discoveries from moving forward.

Bae is principal investigator on the study titled “Biomimetic Vascular Matrix for Vascular Smooth Muscle Cell Mechanobiology and Pathology” that aims to identify potential new therapeutic targets for the treatment of cardiovascular disease.

The lifetime honor is bestowed on AAAS members by their peers for their scientifically or socially distinguished efforts to advance science applications.

EDI is an integrated drug discovery and development accelerator located in upstate New York, and formed as an equal partnership between the University at Buffalo, University of Rochester and Roswell Park Comprehensive Cancer Center.  

Empire Discovery Institute (EDI) entered into a five-year collaborative research partnership with global pharmaceutical company Novo Nordisk A/S to launch LeapRx, a new initiative where EDI and Novo Nordisk will co-invest, incubate and accelerate innovative drug discovery and development projects from its academic partners. 

Pollack’s research focuses on how drugs and toxicants affect the central nervous system.

Established with $35.4 million in initial funding from Empire State Development, it works in partnership with research labs at UB.

Maquat has studied RNA since she started her own laboratory in 1982. But until the development and approval of multiple mRNA COVID-19 vaccines in 2020, RNA wasn’t on the public radar.

In the inaugural year of EDI's Medicines Discovery Award Program, Drs. Denise Hocking and John Lueck each received awards.

ED3 funding and support are expected to be made available for projects evaluated by EDI and Deerfield in high-need therapeutic areas, as well as those targeting patients who suffer from hard-to-treat and rare diseases, to accelerate them towards clinical validation in patients and commercialization.

Deerfield Management Company, a healthcare investment firm focused on advancing healthcare through investment, information and philanthropy, and the Empire Discovery Institute (EDI) have formed a translational research partnership to accelerate the development of novel therapeutics.

Balu-Iyer, a professor in the Department of Pharmaceutical Sciences, leads an innovative and productive research program in the area of protein therapeutics and immunotherapy.

“We represent a nimble and transformative approach to the creation of new medicines,” says Martin Graham, CEO of EDI.

Over a year ago, three major institutions in the Rochester area joined forces to create the Empire Discovery Institute.